Novavax signs COVID-19 vaccine supply deal with India’s Serum Institute
Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.
The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “Pandemic Period” in all countries other than those designated by the World Bank as upper-middle or high-income countries.
The deal was signed on July 30, according to an SEC filing by Novavax.
On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.
The number of deaths from coronavirus in Iran is nearly triple what Iran’s government claims, a BBC Persian service investigation has found.
The government’s own records appear to show almost 42,000 people died with Covid-19 symptoms up to 20 July, versus 14,405 reported by its health ministry.
The number of people known to be infected is also almost double official figures: 451,024 as opposed to 278,827.Iran has been one of the worst-hit countries outside China.
In recent weeks, it has suffered a second steep rise in the number of cases.The first death in Iran from Covid-19 was recorded on 22 January, according to lists and medical records that have been passed to the BBC. This was almost a month before the first official case of coronavirus was reported there.
Daily number of deaths from Covid-19 in Iran
Official figures vs uncovered data, 22 January to 20 July 2020Since the outbreak of the virus in Iran, many observers have doubted the official numbers.
There have been irregularities in data between national and regional levels, which some local authorities have spoken out about, and statisticians have tried to give alternative estimates..